Citadel Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$207M Buy
7,359,865
+1,952,489
+36% +$52M 0.03% 443
2025
Q4
$135M Sell
5,407,376
-4,879,551
-47% -$123M 0.02% 687
2025
Q3
$262M Sell
10,286,927
-4,579,276
-31% -$113M 0.04% 372
2025
Q2
$360M Buy
14,866,203
+7,831,434
+111% +$183M 0.06% 226
2025
Q1
$178M Sell
7,034,769
-7,838,540
-53% -$205M 0.03% 410
2024
Q4
$395M Buy
14,873,309
+6,811,116
+84% +$185M 0.07% 199
2024
Q3
$233M Sell
8,062,193
-12,333,440
-60% -$360M 0.05% 312
2024
Q2
$571M Buy
20,395,633
+7,886,096
+63% +$217M 0.12% 108
2024
Q1
$347M Buy
12,509,537
+879,463
+8% +$24.4M 0.07% 209
2023
Q4
$335M Buy
11,630,074
+9,343,112
+409% +$282M 0.07% 192
2023
Q3
$75.9M Buy
2,286,962
+162,461
+8% +$5.75M 0.02% 783
2023
Q2
$77.9M Buy
2,124,501
+600,673
+39% +$23.4M 0.02% 767
2023
Q1
$62.2M Buy
1,523,828
+330,884
+28% +$14.3M 0.01% 912
2022
Q4
$61.1M Sell
1,192,944
-2,858,017
-71% -$137M 0.01% 971
2022
Q3
$177M Buy
4,050,961
+3,121,361
+336% +$152M 0.04% 354
2022
Q2
$48.7M Sell
929,600
-499,168
-35% -$25.4M 0.01% 1035
2022
Q1
$74M Buy
1,428,768
+447,036
+46% +$23.2M 0.02% 828
2021
Q4
$58M Sell
981,732
-4,336,153
-82% -$215M 0.01% 1054
2021
Q3
$229M Buy
5,317,885
+4,608,491
+650% +$204M 0.05% 300
2021
Q2
$27.8M Sell
709,394
-7,448,658
-91% -$290M 0.01% 1700
2021
Q1
$296M Buy
8,158,052
+2,246,608
+38% +$79.8M 0.07% 179
2020
Q4
$218M Buy
5,911,444
+4,670,668
+376% +$171M 0.06% 236
2020
Q3
$43.2M Buy
1,240,776
+3,884
+0.3% +$136K 0.01% 966
2020
Q2
$38.4M Sell
1,236,892
-7,375,041
-86% -$251M 0.01% 974
2020
Q1
$267M Buy
8,611,933
+5,566,896
+183% +$190M 0.12% 87
2019
Q4
$113M Buy
3,045,037
+1,233,718
+68% +$43.9M 0.05% 343
2019
Q3
$61.7M Buy
1,811,319
+1,203,839
+198% +$43.8M 0.03% 636
2019
Q2
$25M Sell
607,480
-349,101
-36% -$13.9M 0.01% 1218
2019
Q1
$38.5M Buy
956,581
+340,901
+55% +$13.7M 0.02% 849
2018
Q4
$25.5M Sell
615,680
-3,956,306
-87% -$164M 0.01% 1048
2018
Q3
$191M Buy
4,571,986
+4,514,509
+7,854% +$174M 0.09% 183
2018
Q2
$1.98M Sell
57,477
-70,543
-55% -$2.41M ﹤0.01% 4131
2018
Q1
$4.31M Sell
128,020
-82,386
-39% -$2.83M ﹤0.01% 2629
2017
Q4
$7.23M Sell
210,406
-7,089,023
-97% -$242M ﹤0.01% 2051
2017
Q3
$247M Buy
7,299,429
+6,007,603
+465% +$193M 0.19% 63
2017
Q2
$41.2M Buy
1,291,826
+1,018,686
+373% +$32.1M 0.03% 590
2017
Q1
$8.87M Buy
273,140
+20,491
+8% +$646K 0.01% 1529
2016
Q4
$7.79M Buy
252,649
+240,961
+2,062% +$7.36M 0.01% 1578
2016
Q3
$376K Sell
11,688
-1,045,732
-99% -$35M ﹤0.01% 5304
2016
Q2
$35.3M Sell
1,057,420
-426,395
-29% -$13.6M 0.04% 488
2016
Q1
$41.7M Sell
1,483,815
-2,863,114
-66% -$81.8M 0.05% 368
2015
Q4
$133M Buy
4,346,929
+3,515,460
+423% +$111M 0.15% 132
2015
Q3
$24.8M Sell
831,469
-1,665,986
-67% -$53.4M 0.02% 761
2015
Q2
$79.4M Sell
2,497,455
-1,296,893
-34% -$42.3M 0.07% 305
2015
Q1
$125M Buy
3,794,348
+1,489,035
+65% +$47.3M 0.12% 171
2014
Q4
$68.1M Sell
2,305,313
-4,710,832
-67% -$135M 0.07% 329
2014
Q3
$197M Buy
7,016,145
+3,600,733
+105% +$101M 0.21% 71
2014
Q2
$96.2M Sell
3,415,412
-698,814
-17% -$19.9M 0.11% 177
2014
Q1
$125M Sell
4,114,226
-3,059,610
-43% -$91.2M 0.15% 114
2013
Q4
$208M Buy
7,173,836
+7,079,027
+7,467% +$206M 0.27% 47
2013
Q3
$2.58M Sell
94,809
-9,022,015
-99% -$245M ﹤0.01% 2167
2013
Q2
$242M Buy
+9,116,824
New +$252M 0.42% 20

Other funds holding PFE

Citadel Advisors's PFE Position: Q1 2026 in Review

Citadel Advisors increased its Pfizer (PFE) stake by 36% in Q1 2026, buying an estimated $52M and bringing the position to 7,359,865 shares worth $207M. The position accounts for 0.03% of the portfolio, ranked #443.

Citadel Advisors first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $571M in Q2 2024. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Citadel Advisors held 7,359,865 shares of Pfizer worth $207M as of Q1 2026.
  • Citadel Advisors bought 1,952,489 Pfizer shares in Q1 2026, an estimated $52M.
  • Pfizer made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #443 holding.
  • Citadel Advisors first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Pfizer position peaked at $571M in Q2 2024.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.